Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration

Holekamp N.; Campochiaro P.; Chang Margaret A.; Miller Daniel; Pieramici D.; Adamis A.; Brittain C.; Evans Erica; Kaufman D.; Maass K.; Patel Shienal; Ranade S.; Singh Natasha; Barteselli Giulio; Regillo C.

doi:10.1016/j.ophtha.2021.09.016

← Today's brief

L2 StudyUnblinded

Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration

Holekamp N. et al. · Ophthalmology · Friday, January 1, 2021

Read original

Design Level 2n 418Funding Not reported

The one catch: Unblinded, so outcome assessment may be swayed by knowing the assignment.

Source

Holekamp N. et al.. Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. Friday, January 1, 2021.
doi:10.1016/j.ophtha.2021.09.016

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.